

【SR-10 メタアナリシス】

| CQ | | HER2陰性の早期期乳癌に対して、TC療法（ドセタキセル+シクロホスファミド併用療法）は勧められるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|---|---|--------------------------|-------|-------------------|--------------------------|----------------------------------|------|--|--------|----------------------------------|------|--------|-------|--------|-------|------|---|-----|---|-----|------|-------------------|------|------------|-----|------|-----|------|-------|-------------------|------|--------------|----|-----|----|------|-------|-------------------|------|-------|----|------|----|------|-------|-------------------|------|----------------|----|-----|---|----|-------|-------------------|------|-----------------------|-------------|--|-------------|--|---------------|--------------------------|--|--------------|-----|--|-----|--|--|--|--|--|
| P | HER2陰性の早期期乳癌 | I | TC療法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | sequential A+T | O | Febrile neutropeniaの発生割合 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| コード | HORG, ABC trial, DBCG 07-READ, PlanB, Ishiguro et al | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| モデル | Random Effects | 方法 | Inverse Variance | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 効果指標 | Odds ratio | 統合値 | 1.09(0.70-1.68) P=0.71 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| フォレスト プロット | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">A-T</th> <th colspan="2">TC</th> <th rowspan="2">Weight</th> <th rowspan="2">Odds Ratio IV, Random, 95% CI</th> <th rowspan="2">Year</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>HORG</td> <td>3</td> <td>326</td> <td>2</td> <td>324</td> <td>5.0%</td> <td>1.50 [0.25, 9.01]</td> <td>2016</td> </tr> <tr> <td>ABC trials</td> <td>120</td> <td>2061</td> <td>150</td> <td>2089</td> <td>28.5%</td> <td>0.80 [0.62, 1.02]</td> <td>2017</td> </tr> <tr> <td>DBCG 07-READ</td> <td>96</td> <td>994</td> <td>59</td> <td>1006</td> <td>26.5%</td> <td>1.72 [1.23, 2.40]</td> <td>2017</td> </tr> <tr> <td>PlanB</td> <td>45</td> <td>1167</td> <td>63</td> <td>1178</td> <td>25.1%</td> <td>0.71 [0.48, 1.05]</td> <td>2017</td> </tr> <tr> <td>Ishiguro et al</td> <td>26</td> <td>128</td> <td>9</td> <td>65</td> <td>14.9%</td> <td>1.59 [0.69, 3.62]</td> <td>2020</td> </tr> <tr> <td>Total (95% CI)</td> <td colspan="2">4676</td> <td colspan="2">4662</td> <td>100.0%</td> <td>1.09 [0.70, 1.68]</td> <td></td> </tr> <tr> <td>Total events</td> <td colspan="2">290</td> <td colspan="2">283</td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau² = 0.16; Chi² = 17.33, df = 4 (P = 0.002); I² = 77% Test for overall effect: Z = 0.37 (P = 0.71)</p> | | | | Study or Subgroup | A-T | | TC | | Weight | Odds Ratio IV, Random, 95% CI | Year | Events | Total | Events | Total | HORG | 3 | 326 | 2 | 324 | 5.0% | 1.50 [0.25, 9.01] | 2016 | ABC trials | 120 | 2061 | 150 | 2089 | 28.5% | 0.80 [0.62, 1.02] | 2017 | DBCG 07-READ | 96 | 994 | 59 | 1006 | 26.5% | 1.72 [1.23, 2.40] | 2017 | PlanB | 45 | 1167 | 63 | 1178 | 25.1% | 0.71 [0.48, 1.05] | 2017 | Ishiguro et al | 26 | 128 | 9 | 65 | 14.9% | 1.59 [0.69, 3.62] | 2020 | Total (95% CI) | 4676 | | 4662 | | 100.0% | 1.09 [0.70, 1.68] | | Total events | 290 | | 283 | | | | | |
| Study or Subgroup | A-T | | TC | | | Weight | Odds Ratio IV, Random, 95% CI | Year | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Events | Total | Events | Total | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| HORG | 3 | 326 | 2 | 324 | 5.0% | 1.50 [0.25, 9.01] | 2016 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ABC trials | 120 | 2061 | 150 | 2089 | 28.5% | 0.80 [0.62, 1.02] | 2017 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| DBCG 07-READ | 96 | 994 | 59 | 1006 | 26.5% | 1.72 [1.23, 2.40] | 2017 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PlanB | 45 | 1167 | 63 | 1178 | 25.1% | 0.71 [0.48, 1.05] | 2017 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Ishiguro et al | 26 | 128 | 9 | 65 | 14.9% | 1.59 [0.69, 3.62] | 2020 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | 4676 | | 4662 | | 100.0% | 1.09 [0.70, 1.68] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 290 | | 283 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ファンネル プロット | | | | | コメント： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | | | | コメント： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグ レッション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| CQ | HER2陰性の早期期乳癌に対して、TC療法（ドセタキセル+シクロホスファミド併用療法）は勧められるか？ | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| P | HER2陰性の早期期乳癌 | I | TC療法 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| C | sequential A+T | O | G3.4の発生割合 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 研究デザイン | RCT | 文献数 | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| コード | Caparica, Ishiguro | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| モデル | Random Effects | 方法 | Inverse Variance | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|--------------|---------------------------|--------------|---------------|--------------------------|--------------------|--------------------|------------|--|--------|-------|--------|-------|--------------------|--------------------|--------|----|------|----|------|------|-------------------|--|----------|-----|------|-----|------|-------|-------------------|--|-----------------|-----|------|----|------|------|-------------------|--|---------------|----|------|---|------|------|-------------------|--|-----------|-----|------|----|------|------|-------------------|--|-------------|------|------|------|------|-------|-------------------|--|--------------------|-----|------|-----|------|-------|-------------------|--|------------------|----|------|----|------|------|-------------------|--|-----------------------|--|--------------|--|--------------|---------------|--------------------------|--|--------------|------|--|------|--|--|--|--|---|--|--|--|--|--|--|--|---|--|--|--|--|--|--|--|--|
| 効果指標 | Odds ratio | 統合値 | 0.79(0.73-0.85) P<0.00001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| フォレスト プロット | <table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">A+T</th> <th colspan="2">TC</th> <th rowspan="2">Weight</th> <th colspan="2">Odds Ratio</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Fixed, 95% CI</th> <th>M-H, Fixed, 95% CI</th> </tr> </thead> <tbody> <tr> <td>anemia</td> <td>33</td> <td>2515</td> <td>23</td> <td>2478</td> <td>2.0%</td> <td>1.42 [0.83, 2.42]</td> <td></td> </tr> <tr> <td>diarrhea</td> <td>169</td> <td>4548</td> <td>164</td> <td>4597</td> <td>13.6%</td> <td>1.04 [0.84, 1.30]</td> <td></td> </tr> <tr> <td>Emesis vomiting</td> <td>129</td> <td>4548</td> <td>39</td> <td>4597</td> <td>3.3%</td> <td>3.41 [2.38, 4.89]</td> <td></td> </tr> <tr> <td>heart failure</td> <td>15</td> <td>4548</td> <td>9</td> <td>4597</td> <td>0.8%</td> <td>1.69 [0.74, 3.86]</td> <td></td> </tr> <tr> <td>Mucocitis</td> <td>114</td> <td>4548</td> <td>45</td> <td>4597</td> <td>3.8%</td> <td>2.60 [1.84, 3.68]</td> <td></td> </tr> <tr> <td>neutropenia</td> <td>1099</td> <td>3682</td> <td>1077</td> <td>3656</td> <td>65.7%</td> <td>1.02 [0.92, 1.13]</td> <td></td> </tr> <tr> <td>sensory neuropathy</td> <td>197</td> <td>4548</td> <td>121</td> <td>4597</td> <td>10.0%</td> <td>1.67 [1.33, 2.11]</td> <td></td> </tr> <tr> <td>thrombocytopenia</td> <td>48</td> <td>2515</td> <td>11</td> <td>2478</td> <td>0.9%</td> <td>4.36 [2.26, 8.42]</td> <td></td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>31452</td> <td></td> <td>31597</td> <td>100.0%</td> <td>1.27 [1.18, 1.37]</td> <td></td> </tr> <tr> <td>Total events</td> <td>1804</td> <td></td> <td>1489</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Chi² = 86.59, df = 7 (P < 0.00001); I² = 92%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 6.08 (P < 0.00001)</td> </tr> </tbody> </table> | | Study or Subgroup | A+T | | TC | | Weight | Odds Ratio | | Events | Total | Events | Total | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | anemia | 33 | 2515 | 23 | 2478 | 2.0% | 1.42 [0.83, 2.42] | | diarrhea | 169 | 4548 | 164 | 4597 | 13.6% | 1.04 [0.84, 1.30] | | Emesis vomiting | 129 | 4548 | 39 | 4597 | 3.3% | 3.41 [2.38, 4.89] | | heart failure | 15 | 4548 | 9 | 4597 | 0.8% | 1.69 [0.74, 3.86] | | Mucocitis | 114 | 4548 | 45 | 4597 | 3.8% | 2.60 [1.84, 3.68] | | neutropenia | 1099 | 3682 | 1077 | 3656 | 65.7% | 1.02 [0.92, 1.13] | | sensory neuropathy | 197 | 4548 | 121 | 4597 | 10.0% | 1.67 [1.33, 2.11] | | thrombocytopenia | 48 | 2515 | 11 | 2478 | 0.9% | 4.36 [2.26, 8.42] | | Total (95% CI) | | 31452 | | 31597 | 100.0% | 1.27 [1.18, 1.37] | | Total events | 1804 | | 1489 | | | | | Heterogeneity: Chi ² = 86.59, df = 7 (P < 0.00001); I ² = 92% | | | | | | | | Test for overall effect: Z = 6.08 (P < 0.00001) | | | | | | | | |
| | Study or Subgroup | A+T | | TC | | Weight | Odds Ratio | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Events | Total | Events | Total | | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | anemia | 33 | 2515 | 23 | 2478 | 2.0% | 1.42 [0.83, 2.42] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | diarrhea | 169 | 4548 | 164 | 4597 | 13.6% | 1.04 [0.84, 1.30] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Emesis vomiting | 129 | 4548 | 39 | 4597 | 3.3% | 3.41 [2.38, 4.89] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | heart failure | 15 | 4548 | 9 | 4597 | 0.8% | 1.69 [0.74, 3.86] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Mucocitis | 114 | 4548 | 45 | 4597 | 3.8% | 2.60 [1.84, 3.68] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | neutropenia | 1099 | 3682 | 1077 | 3656 | 65.7% | 1.02 [0.92, 1.13] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | sensory neuropathy | 197 | 4548 | 121 | 4597 | 10.0% | 1.67 [1.33, 2.11] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| thrombocytopenia | 48 | 2515 | 11 | 2478 | 0.9% | 4.36 [2.26, 8.42] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total (95% CI) | | 31452 | | 31597 | 100.0% | 1.27 [1.18, 1.37] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total events | 1804 | | 1489 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Heterogeneity: Chi ² = 86.59, df = 7 (P < 0.00001); I ² = 92% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Test for overall effect: Z = 6.08 (P < 0.00001) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ファンネル プロット | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| その他の解析 | : | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| メタリグ レッション | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 感度分析 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |